Incyte Co. (INCY) Stake Lifted by Virtus ETF Advisers LLC

Virtus ETF Advisers LLC grew its position in shares of Incyte Co. (NASDAQ:INCY) by 1,122.8% in the fourth quarter, HoldingsChannel reports. The firm owned 9,073 shares of the biopharmaceutical company’s stock after purchasing an additional 8,331 shares during the period. Virtus ETF Advisers LLC’s holdings in Incyte were worth $577,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in INCY. Rubric Capital Management LP purchased a new position in shares of Incyte during the 3rd quarter valued at $54,894,000. First Trust Advisors LP grew its position in shares of Incyte by 80.8% during the 3rd quarter. First Trust Advisors LP now owns 1,546,098 shares of the biopharmaceutical company’s stock valued at $106,804,000 after purchasing an additional 691,111 shares in the last quarter. BlackRock Inc. grew its position in shares of Incyte by 4.2% during the 3rd quarter. BlackRock Inc. now owns 15,095,211 shares of the biopharmaceutical company’s stock valued at $1,042,778,000 after purchasing an additional 613,119 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Incyte by 351.2% during the 3rd quarter. AQR Capital Management LLC now owns 594,791 shares of the biopharmaceutical company’s stock valued at $41,088,000 after purchasing an additional 462,965 shares in the last quarter. Finally, Worldquant Millennium Quantitative Strategies LLC grew its position in shares of Incyte by 756.9% during the 3rd quarter. Worldquant Millennium Quantitative Strategies LLC now owns 344,645 shares of the biopharmaceutical company’s stock valued at $23,808,000 after purchasing an additional 304,424 shares in the last quarter. Hedge funds and other institutional investors own 89.82% of the company’s stock.

NASDAQ:INCY traded up $1.22 during midday trading on Tuesday, hitting $81.43. The company had a trading volume of 490,873 shares, compared to its average volume of 1,770,516. Incyte Co. has a 52-week low of $57.00 and a 52-week high of $96.33. The firm has a market capitalization of $17.30 billion, a PE ratio of 127.23, a price-to-earnings-growth ratio of 1.04 and a beta of 1.34. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.01 and a current ratio of 4.02.

A number of research firms have recently commented on INCY. Zacks Investment Research lowered shares of Incyte from a “hold” rating to a “strong sell” rating in a research report on Wednesday, January 23rd. TheStreet upgraded shares of Incyte from a “d+” rating to a “c-” rating in a research report on Friday. JMP Securities restated a “hold” rating on shares of Incyte in a research report on Monday. BidaskClub lowered shares of Incyte from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 25th. Finally, ValuEngine upgraded shares of Incyte from a “sell” rating to a “hold” rating in a research report on Tuesday, December 11th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $89.90.

In other Incyte news, EVP Yao Wenqing sold 10,000 shares of the business’s stock in a transaction on Monday, January 7th. The shares were sold at an average price of $75.00, for a total value of $750,000.00. Following the completion of the sale, the executive vice president now directly owns 45,217 shares of the company’s stock, valued at $3,391,275. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paula J. Swain sold 30,000 shares of the business’s stock in a transaction on Friday, January 4th. The stock was sold at an average price of $70.00, for a total transaction of $2,100,000.00. Following the completion of the sale, the executive vice president now directly owns 62,324 shares of the company’s stock, valued at $4,362,680. The disclosure for this sale can be found here. Insiders sold 81,354 shares of company stock valued at $6,058,524 over the last quarter. 17.20% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “Incyte Co. (INCY) Stake Lifted by Virtus ETF Advisers LLC” was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2019/02/12/incyte-co-incy-stake-lifted-by-virtus-etf-advisers-llc.html.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Recommended Story: What kind of dividend yield to CEF’s pay?

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply